IIM
NMRA icon

INTECH Investment Management’s Neumora Therapeutics NMRA Stock Holding History

INTECH Investment Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-73,044
Closed -$73K – 2599
2025
Q1 		$73K Buy
73,044
+39,044
+115% +$66.9K ﹤0.01% 2385
2024
Q4 		$360K Buy
34,000
+20,725
+156% +$248K ﹤0.01% 1737
2024
Q3 		$175K Buy
+13,275
New +$155K ﹤0.01% 1762

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

INTECH Investment Management's NMRA Position: Q2 2025 in Review

INTECH Investment Management sold out of Neumora Therapeutics (NMRA) in Q2 2025, closing a stake of 73,044 shares — an estimated $73K sold.

INTECH Investment Management first reported a position in NMRA in Q3 2024 and held it in 3 quarters. The position peaked at $360K in Q4 2024. 98 funds tracked by Wall St. Rank hold NMRA as of Q2 2025.

  • INTECH Investment Management reported no remaining Neumora Therapeutics position as of Q2 2025 after selling out during the quarter.
  • INTECH Investment Management sold 73,044 Neumora Therapeutics shares in Q2 2025, an estimated $73K.
  • INTECH Investment Management first reported a position in Neumora Therapeutics in Q3 2024 and held it in 3 quarters.
  • INTECH Investment Management's Neumora Therapeutics position peaked at $360K in Q4 2024.
  • 98 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2025.

Based on INTECH Investment Management's 13F filing for Q2 2025, filed 8 Aug 2025.